Search results
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 24 hours agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 1 day agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 4 hours agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 2 hours agoA second failure of a late-stage trial testing a gene therapy to treat Duchenne muscular dystrophy...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 3 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 4 hours agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com
Investing.com· 2 hours agoSarepta Therapeutics (NASDAQ:SRPT) stock rose over 3% Thursday after Pfizer (NYSE:PFE) announced...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 6 hours agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 23 hours agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 1 day agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...